The aim of this study was to clarify the frequency of patients with type 1 diabetes that have serum that increases pancreatic β-cell cytoplasmic free Ca2+ concentration, [Ca2+]i, and if such an effect is also present in serum from first-degree relatives. We also studied a possible link between the serum effect and ethnic background as well as presence of autoantibodies. Sera obtained from three different countries were investigated as follows: 82 Swedish Caucasians with newly diagnosed type 1 diabetes, 56 Americans with different duration of type 1 diabetes, 117 American first-degree relatives of type 1 diabetic patients with a mixed ethnic background and 31 Caucasian Finnish children with newly diagnosed type 1 diabetes. Changes in [Ca2+]i, upon depolarization, were measured in β-cells incubated overnight with sera from type 1 diabetic patients, first-degree relatives or healthy controls. Our data show that there is a group constituting approximately 30% of type 1 diabetic patients of different gender, age, ethnic background and duration of the disease, as well as first-degree relatives of type 1 diabetic patients, that have sera that interfere with pancreatic β-cell Ca2+-handling. This effect on β-cell [Ca2+]i could not be correlated to the presence of autoantibodies. In a defined subgroup of patients with type 1 diabetes and first-degree relatives a defect Ca2+-handling may aggravate development of β-cell destruction.
Skip Nav Destination
Article navigation
Research Article|
November 20 2007
Type 1 Diabetic Serum Interferes with Pancreatic β-cell Ca2+ -Handling
N. Dekki;
N. Dekki
1The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Karolinska University Hospital L1, Stockholm 171 76, Sweden
Search for other works by this author on:
R. Nilsson;
R. Nilsson
1The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Karolinska University Hospital L1, Stockholm 171 76, Sweden
Search for other works by this author on:
S. Norgren;
S. Norgren
2Department of Clinical Sciences, Division of Pediatrics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
Search for other works by this author on:
S. M. Rössner;
S. M. Rössner
2Department of Clinical Sciences, Division of Pediatrics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
Search for other works by this author on:
I. Appelskog;
I. Appelskog
1The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Karolinska University Hospital L1, Stockholm 171 76, Sweden
Search for other works by this author on:
C. Marcus;
C. Marcus
2Department of Clinical Sciences, Division of Pediatrics, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
Search for other works by this author on:
O. Simell;
O. Simell
3Department of Pediatrics, University of Turku, Turku, Finland
Search for other works by this author on:
A. Pugliese;
A. Pugliese
4The Diabetes Research Institute, University of Miami, School of Medicine, Miami, USA
Search for other works by this author on:
R. Alejandro;
R. Alejandro
4The Diabetes Research Institute, University of Miami, School of Medicine, Miami, USA
Search for other works by this author on:
C. Ricordi;
C. Ricordi
4The Diabetes Research Institute, University of Miami, School of Medicine, Miami, USA
Search for other works by this author on:
P. O. Berggren;
P. O. Berggren
1The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Karolinska University Hospital L1, Stockholm 171 76, Sweden
Search for other works by this author on:
L. Juntti-Berggren
L. Juntti-Berggren
1The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska Institutet, Karolinska University Hospital L1, Stockholm 171 76, Sweden
Search for other works by this author on:
Biosci Rep (2007) 27 (6): 321–326.
Citation
N. Dekki, R. Nilsson, S. Norgren, S. M. Rössner, I. Appelskog, C. Marcus, O. Simell, A. Pugliese, R. Alejandro, C. Ricordi, P. O. Berggren, L. Juntti-Berggren; Type 1 Diabetic Serum Interferes with Pancreatic β-cell Ca2+ -Handling. Biosci Rep 20 November 2007; 27 (6): 321–326. doi: https://doi.org/10.1007/s10540-007-9055-y
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.